Key Highlights

  • Cochlear Limited (ASX:COH): FY26 sales Revenue reached AUD 2.343 billion, representing 2% growth in constant currency.
  • Underlying net profit was AUD 322 million, a decrease of 22% year on year.
  • Cochlear implant sales revenue reached AUD 1.435 billion, with a 5% increase in the number of implants sold.
  • The Nucleus Nexa system represented more than 95% of developed-market implant mix by June 2026.
  • FY26 dividends totalled AUD 3.45 per share, a decrease of 20% from FY25.

Cochlear Limited (ASX:COH) develops hearing implants, sound processors and associated hearing-care systems. The FY26 results presentation dated 18 August 2026 showed modest sales growth in constant currency alongside a decline in underlying profit. Product launches and an increase in implant volumes provided operating progress, but regional Demand and cost factors affected profitability. The company also discussed initiatives to support patient referral pathways and growth in hearing treatment adoption.

Sales and Profit Outcome

Sales revenue increased 2% in constant currency to AUD 2.343 billion for FY26. Growth accelerated in the second half, when constant-currency sales increased 6%. The company reported that the full-year result met its revised guidance.

Underlying net profit was AUD 322 million, down 22% from FY25. This contrasted with revenue growth and indicates that changes in operating expenses, product mix and other factors affected earnings. The company’s underlying definition excludes significant items and should not be confused with statutory profit.

Cochlear Implants and New Platform

Cochlear implant revenue reached AUD 1.435 billion and represented 61% of overall revenue. Revenue for the implant group was broadly flat in constant currency, although implant units sold increased 5%.

The Nucleus Nexa platform accounted for more than 95% of the developed-market implant mix by June 2026, with an average 3% price increase reported for that mix. Unit sales and revenue therefore moved differently, reinforcing the role of regional mix and pricing in interpreting the annual result.

Regional Performance

Developed-market implant revenue increased 1% in constant currency. Within that group, United States revenue increased 4%, while Western Europe declined 8%, with the company identifying country-specific constraints on procedures.

Asia Pacific revenue increased 7% in constant currency. Emerging-market revenue declined 2%, reflecting different conditions across regions. These comparisons show that global results were affected by varied reimbursement environments, demand patterns and access to implant procedures.

Access Initiatives and Capital Returns

COH reported 10% growth in its United States direct-to-consumer surgery channel, with efforts to improve patient referral and treatment pathways. Such initiatives seek to support access to hearing implants, although the ultimate conversion to surgeries depends on clinical assessment and healthcare systems.

The FY26 Dividend totalled AUD 3.45 per share, down 20% from the prior year. The presentation also described planned reductions in fixed costs and continued Investment in research and development. These plans represent management actions rather than realised future profit.

Key Insights

COH’s FY26 results showed growth in implant volumes and wider use of its Nexa technology, while Underlying Profit declined. The regional figures illustrate uneven market conditions, especially in Europe compared with parts of Asia Pacific. Further reporting will indicate whether referral initiatives, product adoption and cost measures can translate into stronger operating earnings.